You are choosing how to build, not just who builds. The decision between staff augmentation, a dedicated team, and outsourcing looks like a procurement question. In regulated healthcare, it is a compliance question wearing a procurement disguise.

Staff augmentation, dedicated team, and outsourcing differ less in cost than in where your compliance boundary sits. Staff augmentation keeps engineers inside your boundary on a time-and-materials basis. A dedicated team is a vendor-run squad following your roadmap. Outsourcing hands a defined deliverable to a vendor who owns the process.

The generic comparison articles optimize for the wrong failure. They worry about sprint collapse and management overhead. Those matter, but they are not the risk that ends a company in this sector. The risk is the auditor who asks for your traceability matrix and finds three vendors each assumed someone else was keeping it.

Staff augmentation, dedicated team, and outsourcing, defined for regulated work

Three engagement models dominate healthcare software work. They are not three flavors of the same thing.

Staff augmentation puts external engineers inside your organization. They work under your roadmap, your tools, your QMS, billed by time and materials. You manage them. The legal and compliance boundary does not move — it still ends at your perimeter, with contractors working inside it.

A dedicated team is a vendor-run squad assigned to you, usually at a fixed monthly fee. The vendor handles hiring, retention, and team management. You set direction. The boundary becomes shared, and where exactly it sits is something you negotiate rather than assume.

Outsourcing — also called project-based or fixed-scope delivery — hands a defined deliverable to a vendor who owns the process end to end. You specify the outcome. They decide how to reach it, inside their environment and their QMS. The boundary moves to them.

Is staff augmentation the same as outsourcing? Both bring in outside labor, so the terms get used loosely. They are not the same.

Staff augmentation fills a talent gap inside your boundary; outsourcing relocates a unit of work — and its accountability — outside it. The distinction is trivial in unregulated SaaS. In healthcare it determines who answers to the auditor.

The axis that matters is not control versus cost. It is where your compliance boundary sits once the contract is signed.

Engineering and QA for healthcare teams that can't afford execution risk

Why this is a compliance decision before it's a cost decision

Your extended team is part of your audit surface. Every model. There is no arrangement where bringing in outside engineers leaves your regulatory posture untouched — it only changes how.

Each model relocates three things: who can touch PHI, how visible your SDLC is to you, and who runs incident response when something breaks.

  • Staff augmentation keeps all three inside your systems, logged by your tooling.

  • Outsourcing pushes them into an environment you see through reports, not directly.

  • A dedicated team splits them, often across a mixed environment where access logs live in two places.

This is where a common error does real damage. There is no "HIPAA certification" for a custom healthcare development partner. No vendor holds a HIPAA badge, because HIPAA does not issue one. Compliance is demonstrated through a signed Business Associate Agreement, implemented safeguards, and audit evidence — not a certificate on a sales deck.

What you should look for are real attestations: a signed BAA that names your vendor a business associate, SOC 2 Type II reporting on operating effectiveness over time, and — for device work — ISO 13485 and ISO 27001. These are verifiable. "HIPAA certified" is not.

And outsourcing does not transfer your liability. This is the most expensive misunderstanding in the category. You can move the work outside your walls. You cannot move the obligation. Under HIPAA you remain the covered entity; under FDA regulation you remain the manufacturer of record. A vendor's mistake is still your violation.

Control, cost, scaling, and audit posture, side by side

Staff augmentation
Dedicated team
Project outsourcing

Day-to-day control

Yours

Shared — vendor runs the team, you set direction

Vendor's

Billing structure

Time and materials

Fixed monthly fee

Fixed scope / milestone

Scaling speed

Fast — add or drop people

Moderate — team ramps as a unit

Slow — rescope and recontract

Scope change

Absorbs easily

Absorbs with notice

Triggers a change order

SDLC visibility

Full — your tools, your logs

Partial — mixed environment

Reported, not direct

Audit readiness

Yours to maintain

Co-owned — define it in the contract

Depends on vendor evidence and your access to it

Exit / knowledge transfer

Low risk — IP and context stay

Moderate — plan the handoff

Highest risk — knowledge can leave with the vendor

Which model is cheapest for healthcare software? None of them, universally. The honest answer the comparisons keep repeating is correct as far as it goes: cost depends on duration, requirement clarity, and how much management capacity you have.

Time-and-materials looks expensive per hour and stays flexible.
Fixed-bid looks cheap and punishes change.

In regulated work the cost question has a second half nobody attaches. The cheapest-looking fixed bid is often the most expensive once V&V rework and documentation gaps surface in audit. A price that excludes traceability, design history, and validation evidence is not a lower price. It is a deferred bill, payable at the worst possible moment — a week before submission.

Who holds the audit evidence? A model-by-model ownership map

Every comparison argues control, cost, and speed. None answers the question a regulator cares about. When the auditor arrives, who is custodian of the evidence — and is it admissible?

The artifacts an auditor demands do not care about your org chart. They care about who can produce them, complete and traceable, on request. The model you choose silently assigns custody of each one.

Audit artifact
Staff augmentation
Dedicated team
Project outsourcing

BAA / legal data custodian

You — engineers sit inside your boundary

Shared; a BAA with the vendor is required

Vendor handles PHI; you inherit their controls

QMS the work runs under (ISO 13485)

Your QMS

Negotiable — decide whose QMS governs

Vendor's QMS

Design History File / traceability matrix

You assemble it

Co-owned — define the handoff up front

Vendor assembles; transfer risk on exit

V&V evidence (IEC 62304 §5.5–5.7)

Your process, their hands

Vendor process, your review

Vendor's; visibility gap on test access

Access logs for the audit window

Your systems capture everything

Mixed environment, logs in two places

Shadow-environment risk — you may not see who touched PHI in testing

Legal manufacturer of record (SaMD)

You

You

You — outsourcing does not move this

Read the bottom row twice. Across all three models, the manufacturer of record is you. The work is delegable. The obligation is not.

That distinction holds even for the most hands-off arrangement. A vendor can review, validate, and build. But the regulatory process is yours to own, and you bear the burden of proving any deviation.

Get the custody assignment wrong and the penalty is not abstract. As of January 28, 2026, HIPAA's top enforcement tier — willful neglect left uncorrected — runs from $73,011 to $2,190,294 per violation, with a $2,190,294 annual cap (Federal Register, 2026-01688). Inadequate BAAs with vendors who handle PHI sit among the most common violation categories. The gap that triggers one is rarely dramatic. It is usually a missing log from a testing environment nobody agreed to audit.

Tell us what you're building. We'll tell you what it takes to do it right.

The SaMD and medical-device buyer: a different calculus

If your software is a medical device — Software as a Medical Device, or software inside one — the engagement-model math changes. The obligations attach to a lifecycle, and that lifecycle does not move when the work does.

IEC 62304 obligations don't move with the work

IEC 62304 governs the software lifecycle for medical devices: planning, requirements, architecture, detailed design, verification, integration, and maintenance, with documentation at each stage. The standard binds the manufacturer. A vendor can execute against it. A vendor cannot become the manufacturer accountable for it. Outsource development of Class C software, let the vendor's lifecycle documentation drift, and the gaps are yours at audit.

21 CFR Part 11, ISO 14971, and design controls — who runs them

Three obligations sit underneath device software, and each one assigns badly under fixed-scope outsourcing. 21 CFR Part 11 demands controlled, attributable electronic records — which means you need the audit trail from the vendor's systems, not a summary of it. ISO 14971 risk management is continuous and tied to your design inputs, not a deliverable a vendor closes out. Design controls require traceability from user need to verification, maintained as the product changes — not frozen at handover.

Why fixed-bid is the highest-risk model for Class II and III

For Class II and III device software, a fully outsourced fixed bid is the worst fit. The model rewards the vendor for closing scope, while your obligations stay open for the life of the device. When the FDA asks for V&V evidence two years after delivery, the team that produced it may be gone and the traceability may have left with them. That is the lock-in risk in medical software made concrete: the people leave, and the evidence leaves with them.

Staff augmentation, or a dedicated team co-owning the QMS, usually fits regulated device work better. The engineers change; the evidence stays inside your boundary, under your controls, available when a submission or an inspection demands it.

A decision framework: which model fits your situation

No model is correct in general. Each is correct for a specific regulatory posture. Three triggers decide it.

  • Choose staff augmentation when you have in-house engineering leadership and a QMS that already works. You need capacity and healthcare fluency, not a new operating model. The boundary stays yours; you are adding hands inside it.

  • Choose a dedicated team when you have a long roadmap and stable direction but do not want to run hiring and team management yourself. You get continuity without managing it day to day — provided you settle whose QMS governs and who assembles the Design History File before work starts.

  • Choose outsourcing when the work is scoped, non-core, and cleanly separable — and you can own the audit trail it produces. A standalone integration or a contained module can be outsourced well. A Class C device's core software usually cannot.

Many teams in digital health and healthtech run a hybrid: the core product team augmented inside the boundary, a scoped module outsourced separately. It works — but only with boundary discipline. The moment the outsourced module touches PHI or feeds the device's intended use, its evidence has to flow back into your QMS, not sit in the vendor's.

This is the logic behind how Flyant structures engagement.

  • Embed places healthcare-fluent engineers inside your boundary.

  • Build owns end-to-end product engineering.

  • Assure runs healthcare quality engineering and test automation.

  • Evolve modernizes certified platforms without breaking what is already certified.

The labels are not the point. The point is that the engagement model and the regulatory posture get decided together, not in sequence.

Across 16 years and 30-plus healthcare products, the pattern holds: the teams that pass audits are the ones that assigned evidence custody on day one. Flyant has not failed a regulatory audit. That is a function of where the evidence sits, not luck.

Questions to ask any partner before you sign

Five questions separate a partner who understands regulated work from one who becomes your next audit finding.

  • Can your engineers work inside our QMS, or only their own?

  • Will you sign a BAA and name yourself a business associate?

  • Can you produce access logs covering our audit window, from every environment your team touches?

  • Who assembles the Design History File and traceability matrix — and where does it live?

  • What is the exit and knowledge-transfer plan if we part ways mid-lifecycle?

If a vendor cannot answer the third and fourth questions cleanly, the model they are selling will not survive your next inspection.

Hold us to all these questions

The engagement model you choose is the first compliance decision you make on a healthcare product — usually before anyone calls it one. Decide it with the auditor in mind, and the rest of the program gets easier.

When you are ready to map your build to the regulatory posture it requires, Flyant can help you draw the boundary in the right place.

Frequently Asked Questions

Both bring in external talent, but they solve different problems. Staff augmentation fills a capability gap with engineers who work inside your boundary, under your management and QMS. Outsourcing hands a defined deliverable to a vendor who owns the process outside your boundary. In regulated work, that difference decides who holds the audit evidence.
None universally. Cost depends on duration, requirement clarity, and your management capacity. Time-and-materials staff augmentation stays flexible but costs more per hour; fixed-bid outsourcing looks cheaper until V&V rework and documentation gaps surface in audit. In regulated work, the lowest sticker price is often the highest total cost.
Yes, and many teams do. A common pattern is a core product team augmented inside your boundary plus a scoped, separable module outsourced to a vendor. It works only with boundary discipline: any evidence the outsourced module generates — access logs, validation records — has to flow back into your QMS.
No. You can delegate the work; you cannot delegate the obligation. Under HIPAA you remain the covered entity. Under FDA regulation you remain the manufacturer of record. A vendor's compliance failure is still your violation, and your penalty.
Outsourcing's biggest risk is evidence and knowledge leaving with the vendor — a visibility gap that surfaces at audit. Staff augmentation's is management overhead and the cost of carrying the boundary yourself. A dedicated team's is ambiguity: an undefined QMS and unassigned artifact ownership that nobody notices until the auditor does.

Didn’t find the answer you are looking for?

Contact us
Oleg Sadikov

Oleg Sadikov

CEO

Oleg Sadikov is the Chief Executive Officer and co-founder of Flyant. He started the company with a clear vision: to raise the bar for healthcare software quality and turn QA into a genuine business enabler rather than a formality in the delivery process. Under his leadership, Flyant has built and scaled a global engineering and QA organization focused on real product outcomes, with quality strategy that stays aligned to each client's business goals.